Vincent, Andrea published the artcileIdentification of candidate drugs for the treatment of ALS, Related Products of ethers-buliding-blocks, the publication is Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders (2005), 6(1), 29-36, database is CAplus and MEDLINE.
A consortium of investigators interested in neurodegenerative diseases collaborated to screen 1040 drugs in multiple neurodegenerative disease assays. One model of amyotrophic lateral sclerosis (ALS) pathogenesis in particular incorporated glutamate exposure in enriched primary rat motor neuron cultures. In this model 78 compounds decreased motor neuron death caused by 100 μM glutamate. Almost all these pharmacol. agents act at one or more of the following cellular targets: (1) protein synthesis inhibition; (2) Cox inhibition; (3) regulation of anion flux; (4) modulation of GABA receptors; (5) antioxidant, and (6) cell cycle inhibition. The most prevalent mode of action was the regulation of intracellular calcium. These data extend the understanding of motor neuron degeneration and identify a number of cellular targets for the improvement of combined therapies for neurodegenerative disease.
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders published new progress about 637-58-1. 637-58-1 belongs to ethers-buliding-blocks, auxiliary class Inhibitor, name is 4-(3-(4-Butoxyphenoxy)propyl)morpholine hydrochloride, and the molecular formula is C42H63O3P, Related Products of ethers-buliding-blocks.
Referemce:
https://en.wikipedia.org/wiki/Ether,
Ether | (C2H5)2O – PubChem